cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase - PubMed (original) (raw)

cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase

M A Moro et al. Proc Natl Acad Sci U S A. 1996.

Abstract

The L-arginine:nitric oxide (NO) pathway is believed to exert many of its physiological effects via stimulation of the soluble guanylyl cyclase (SGC); however, the lack of a selective inhibitor of this enzyme has prevented conclusive demonstration of this mechanism of action. We have found that the compound 1H-[1,2,4]oxadiazolo[4,3,-a]quinoxalin-1-one (ODQ) inhibits the elevation of cGMP induced by the NO donor S-nitroso-DL-penicillamine in human platelets and rat vascular smooth muscle (IC50 = 10-60 nM and <10 nM, respectively) and that this is accompanied by prevention of the platelet inhibitory and vasodilator actions of NO donors. ODQ also inhibited the antiaggregatory action of NO generated by the platelets but did not affect the action of prostacyclin or that of a cGMP mimetic. In addition, ODQ inhibited the vasodilator actions of endogenously released NO and of NO generated after induction of NO synthase in vascular preparations. It did not, however, affect the increase in vascular smooth muscle cGMP or the dilatation induced by atrial natriuretic factor. ODQ had no effect on NO synthase activity, nor did it react with NO. It did, however, potently (IC50 approximately 10 nM) inhibit the activity of the SGC in cytosol obtained from crude extract of rat aortic smooth muscle. Thus ODQ prevents the actions of NO on platelets and vascular smooth muscle through its potent inhibitory effect on the SGC.

PubMed Disclaimer

Cited by

Overview of Antagonists Used for Determining the Mechanisms of Action Employed by Potential Vasodilators with Their Suggested Signaling Pathways.
Loh YC, Tan CS, Ch'ng YS, Ahmad M, Asmawi MZ, Yam MF. Loh YC, et al. Molecules. 2016 Apr 15;21(4):495. doi: 10.3390/molecules21040495. Molecules. 2016. PMID: 27092479 Free PMC article. Review.
Lebetin 2, a Snake Venom-Derived Natriuretic Peptide, Attenuates Acute Myocardial Ischemic Injury through the Modulation of Mitochondrial Permeability Transition Pore at the Time of Reperfusion.
Tourki B, Matéo P, Morand J, Elayeb M, Godin-Ribuot D, Marrakchi N, Belaidi E, Messadi E. Tourki B, et al. PLoS One. 2016 Sep 12;11(9):e0162632. doi: 10.1371/journal.pone.0162632. eCollection 2016. PLoS One. 2016. PMID: 27618302 Free PMC article.
Positive inotropic effects of carbon monoxide-releasing molecules (CO-RMs) in the isolated perfused rat heart.
Musameh MD, Fuller BJ, Mann BE, Green CJ, Motterlini R. Musameh MD, et al. Br J Pharmacol. 2006 Dec;149(8):1104-12. doi: 10.1038/sj.bjp.0706939. Epub 2006 Oct 23. Br J Pharmacol. 2006. PMID: 17057755 Free PMC article.
Carbon monoxide rescues ischemic lungs by interrupting MAPK-driven expression of early growth response 1 gene and its downstream target genes.
Mishra S, Fujita T, Lama VN, Nam D, Liao H, Okada M, Minamoto K, Yoshikawa Y, Harada H, Pinsky DJ. Mishra S, et al. Proc Natl Acad Sci U S A. 2006 Mar 28;103(13):5191-6. doi: 10.1073/pnas.0600241103. Epub 2006 Mar 21. Proc Natl Acad Sci U S A. 2006. PMID: 16551742 Free PMC article.
PF9404C, a new slow NO donor with beta receptor blocking properties.
Villarroya M, Herrero CJ, Ruíz-Nuño A, de Pascual R, del Valle M, Michelena P, Grau M, Carrasco E, López MG, García AG. Villarroya M, et al. Br J Pharmacol. 1999 Dec;128(8):1713-22. doi: 10.1038/sj.bjp.0702992. Br J Pharmacol. 1999. PMID: 10588927 Free PMC article.

References

1. Br J Pharmacol. 1993 Oct;110(2):633-8 - PubMed
1. Br J Pharmacol. 1992 Nov;107(3):745-9 - PubMed
1. Nature. 1994 Apr 28;368(6474):850-3 - PubMed
1. Biochem J. 1994 Aug 1;301 ( Pt 3):645-7 - PubMed
1. Mol Pharmacol. 1995 Aug;48(2):184-8 - PubMed

cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase - PubMed (original) (raw)